OBD
NEUTRALOxford BioDynamics' UK Lab Accredited by UKAS for EpiSwitch Testing
The diagnostics company has received accreditation for its UK lab to run its proprietary EpiSwitch tests, improving turnaround times for customers in the region.
Oxf BioDynamics
0.4065GBX
4.23%
Market Cap
8.16M
Volume
8.26M
62% of avg
P/E Ratio
-0.14
EPS (TTM)
-0.03
Beta
-0.21
Day Range
0.4000p - 0.4500p
52 Week Range
0.3500p0.4065p9.1800p
0.4065p
Upcoming Events
Q1 2026
Potential Commercialization of CRC Test (Q1 2026)
High Impact Event
OBD
NEUTRALOxford BioDynamics Director Increases Stake
The biotechnology company announced a director has purchased a small number of shares.
OBD
NEUTRALOxford BioDynamics Announces PDMR Share Transfer
The biotechnology company has announced a transfer of shares by its Chief Financial Officer into his ISA account.
OBD
NEUTRALOxford BioDynamics Appoints New Non-Executive Director
The biotechnology company has appointed a new Non-Executive Director and Chair of the Audit Committee.
OBD
NEUTRALOxford BioDynamics Announces Change in Major Shareholding
The biotechnology company has announced a change in major shareholding, with Spreadex LTD increasing its stake.
OBD
GOODOxford BioDynamics expands Bupa UK insurance partnership for EpiSwitch PSE prostate cancer test
The biotechnology company has expanded its partnership with Bupa UK insurance to provide customers access to its advanced prostate cancer detection test, which significantly outperforms the standard PSA test.
OBD
NEUTRALOxford BioDynamics Publishes 2024 Annual Report
The biotechnology company has published its annual report for the year ended 30 September 2024.
OBD
NEUTRALOxford BioDynamics Grants Share Options to Executives
The biotechnology company has granted share options to its executives as part of their compensation packages.
OBD
VERY BADOxford BioDynamics Reports Widening Losses and Going Concern Uncertainties in FY24 Results
The biotechnology firm reported widening losses and material uncertainties about its ability to continue as a going concern, despite a slight increase in revenue and progress in product development.
OBD
NEUTRALOxford BioDynamics to Announce Preliminary Results
The biotechnology company will release its preliminary annual results later this month, but the announcement provides limited details on the company's performance.